Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

被引：128

作者：

Heerding, Dirk A. ^{[1
]}

Rhodes, Nelson ^{[1
]}

Leber, Jack D. ^{[1
]}

Clark, Tammy J. ^{[1
]}

Keenan, Richard M. ^{[1
]}

Lafrance, Louis V. ^{[1
]}

Li, Mei ^{[1
]}

Safonov, Igor G. ^{[1
]}

Takata, Dennis T. ^{[1
]}

Venslavsky, Joseph W. ^{[1
]}

Yamashita, Dennis S. ^{[1
]}

Choudhry, Anthony E. ^{[1
]}

Copeland, Robert A. ^{[1
]}

Lai, Zhihong ^{[1
]}

Schaber, Michael D. ^{[1
]}

Tummino, Peter J. ^{[1
]}

Strum, Susan L. ^{[1
]}

Wood, Edgar R. ^{[1
]}

Duckett, Derek R. ^{[1
]}

Eberwein, Derek ^{[1
]}

Knick, Victoria B. ^{[1
]}

Lansing, Timothy J. ^{[1
]}

McConnell, Randy T. ^{[1
]}

Zhang, ShuYun ^{[1
]}

Minthorn, Elisabeth A. ^{[1
]}

Concha, Nestor O. ^{[1
]}

Warren, Gregory L. ^{[1
]}

Kumar, Rakesh ^{[1
]}

机构：

[1] GlaxoSmithKline, Oncol Ctr Excellence Drug Discovery, Collegeville, PA 19426 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 18期

关键词：

D O I：

10.1021/jm8004527

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies cultriinating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3 beta. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3 beta phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.

引用

页码：5663 / 5679

页数：17

共 31 条

[21] Lindsley CW, 2007, CURR TOP MED CHEM, V7, P1349
[22] Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Luo, Y
Shoemaker, AR
Liu, XS
Woods, KW
Thomas, SA
de Jong, R
Han, EK
Li, TM
Stoll, VS
Powlas, JA
Oleksijew, A
Mitten, MJ
Shi, Y
Guan, R
McGonigal, TP
Klinghofer, V
Johnson, EF
Leverson, JD
Bouska, JJ
Mamo, M
Smith, RA
Gramling-Evans, EE
Zinker, BA
Mika, AK
Nguyen, PT
Oltersdorf, T
Rosenberg, SH
Li, Q
Giranda, VL
[J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (06) : 977 - 986
[23] Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines
Nakatani, K
Thompson, DA
Barthel, A
Sakaue, H
Liu, W
Weigel, RJ
Roth, RA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) : 21528 - 21532
[24] Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines
Nicholson, KM
Streuli, CH
Anderson, NG
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 81 (02) : 117 - 128
[25] Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Rhodes, Nelson
Heerding, Dirk A.
Duckett, Derek R.
Eberwein, Derek J.
Knick, Victoria B.
Lansing, Timothy J.
McConnell, Randy T.
Gilmer, Tona M.
Zhang, Shu-Yun
Robell, Kimberly
Kahana, Jason A.
Geske, Robert S.
Kleymenova, Elena V.
Choudhry, Anthony E.
Lai, Zhihong
Leber, Jack D.
Minthornn, Elisabeth A.
Strum, Susan L.
Wood, Edgar R.
Huang, Pearl S.
Copeland, Robert A.
Kumar, Rakesh
[J]. CANCER RESEARCH, 2008, 68 (07) : 2366 - 2374
[26] Rusnak DW, 2001, MOL CANCER THER, V1, P85
[27] A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates
Shults, MD
Janes, KA
Lauffenburger, DA
Imperiali, B
[J]. NATURE METHODS, 2005, 2 (04) : 277 - 283
[28] Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity
Stavenger, Robert A.
Cui, Haifeng
Dowdell, Sarah E.
Franz, Robert G.
Gaitanopoulos, Dimitri E.
Goodman, Krista B.
Hilfiker, Mark A.
Ivy, Robert L.
Leber, Jack D.
Marino, Joseph P., Jr.
Oh, Hye-Ja
Viet, Andrew Q.
Xu, Weiwei
Ye, Guosen
Zhang, Daohua
Zhao, Yongdong
Jolivette, Larry J.
Head, Martha S.
Semus, Simon F.
Elkins, Patricia A.
Kirkpatrick, Robert B.
Dul, Edward
Khandekar, Sanjay S.
Yi, Tracey
Jung, David K.
Wright, Lois L.
Smith, Gary K.
Behm, David J.
Doe, Christopher P.
Bentley, Ross
Chen, Zunxuan X.
Hu, Erding
Lee, Dennis
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (01) : 2 - 5
[29] A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
Wood, ER
Truesdale, AT
McDonald, OB
Yuan, D
Hassell, A
Dickerson, SH
Ellis, B
Pennisi, C
Horne, E
Lackey, K
Alligood, KJ
Rusnak, DW
Gilmer, TM
Shewchuk, L
[J]. CANCER RESEARCH, 2004, 64 (18) : 6652 - 6659
[30] Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP
Yang, J
Cron, P
Good, VM
Thompson, V
Hemmings, BA
Barford, D
[J]. NATURE STRUCTURAL BIOLOGY, 2002, 9 (12) : 940 - 944

← 1 2 3 4 →